What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Subcutaneous or intravenous injection of levilimab with placebo.”In the company’s words, NCT05800327 on ClinicalTrials.gov
- Tested for
- Rheumatoid Arthritis
- Main trialPhase 3
- “This is a two-stage study of efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of various doses of levilimab when administered intravenously and subcutaneously to healthy subjects and subjects with active rheumatoid arthritis resistant to methotrexate monotherapy. Aim of the Stage 1 is to study the tolerability, safety, immunogenicity, and main pharmacokinetic and pharmacodynamic parameters of levilimab after its single subcutaneous or intravenous administration at ascending doses to healthy subjects. Aim of the Stage 2 is to confirm the efficacy and safety of…”In the company’s words, NCT05800327 on ClinicalTrials.gov
- Other names
- BCD-089
Other drugs for Rheumatoid Arthritis
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- UpadacitinibAbbVie · Phase 3
- AbataceptBristol Myers Squibb · Phase 3
- AdalimumabAbbVie · Phase 3
- AnakinraSwedish Orphan Biovitrum · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Sep 2024 | A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis | |
| Phase 3Completed | 3 Jul 2020 | A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19 | |
| Phase 3Completed | 15 Mar 2021 | Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis | |
| Phase 2Completed | 31 Dec 2018 | The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis | |
| Phase 1Completed | May 2017 | First-in-human Study of Safety, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-089 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026